Vor Biopharma (VOR) Competitors $2.00 -0.04 (-1.96%) Closing price 04:00 PM EasternExtended Trading$2.01 +0.01 (+0.50%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VOR vs. PRAX, CRMD, CRON, NUVB, VERV, VALN, MLYS, ATAI, IOVA, and UPBShould you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Praxis Precision Medicines (PRAX), CorMedix (CRMD), Cronos Group (CRON), Nuvation Bio (NUVB), Verve Therapeutics (VERV), Valneva (VALN), Mineralys Therapeutics (MLYS), atai Life Sciences (ATAI), Iovance Biotherapeutics (IOVA), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. Vor Biopharma vs. Its Competitors Praxis Precision Medicines CorMedix Cronos Group Nuvation Bio Verve Therapeutics Valneva Mineralys Therapeutics atai Life Sciences Iovance Biotherapeutics Upstream Bio Praxis Precision Medicines (NASDAQ:PRAX) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings. Is PRAX or VOR more profitable? Vor Biopharma has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -2,137.48%. Vor Biopharma's return on equity of 0.00% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines-2,137.48% -60.07% -54.84% Vor Biopharma N/A N/A N/A Do insiders and institutionals believe in PRAX or VOR? 67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 2.7% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 0.5% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has preferable valuation and earnings, PRAX or VOR? Vor Biopharma has lower revenue, but higher earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPraxis Precision Medicines$8.55M114.61-$182.82M-$12.29-3.79Vor BiopharmaN/AN/AN/A-$13.66-0.15 Does the media prefer PRAX or VOR? In the previous week, Praxis Precision Medicines had 3 more articles in the media than Vor Biopharma. MarketBeat recorded 12 mentions for Praxis Precision Medicines and 9 mentions for Vor Biopharma. Praxis Precision Medicines' average media sentiment score of 1.21 beat Vor Biopharma's score of -0.33 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vor Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer PRAX or VOR? Praxis Precision Medicines presently has a consensus target price of $85.88, indicating a potential upside of 84.48%. Vor Biopharma has a consensus target price of $6.07, indicating a potential upside of 203.33%. Given Vor Biopharma's higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Praxis Precision Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Praxis Precision Medicines 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78Vor Biopharma 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56 Which has more risk & volatility, PRAX or VOR? Praxis Precision Medicines has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. SummaryPraxis Precision Medicines beats Vor Biopharma on 8 of the 14 factors compared between the two stocks. Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VOR vs. The Competition Export to ExcelMetricVor BiopharmaBiological Products, Except Diagnostic Substances IndustryMedical SectorNYSE ExchangeMarket Cap$253.37M$232.53M$5.75B$21.15BDividend YieldN/AN/A6.66%3.51%P/E Ratio-1.21N/A82.4429.10Price / SalesN/A323.34530.5947.93Price / CashN/AN/A25.7018.29Price / BookN/A4.5210.645.30Net IncomeN/A-$111.70M$3.28B$998.51M7 Day PerformanceN/A-0.44%-0.08%-0.57%1 Month Performance-4.76%-19.76%10.35%6.43%1 Year Performance140.01%140.01%48.99%13.75% Vor Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VORVor Biopharma1.9668 of 5 stars$2.00-2.0%$6.07+203.3%+133.4%$253.37MN/A-1.21140PRAXPraxis Precision Medicines2.8955 of 5 stars$46.94-3.8%$85.88+82.9%-15.4%$1.03B$8.55M0.00110Analyst ForecastCRMDCorMedix3.4139 of 5 stars$13.73+0.3%$16.71+21.7%+134.6%$1.02B$43.47M18.2530News CoveragePositive NewsShort Interest ↑CRONCronos Group1.6544 of 5 stars$2.60-0.2%N/A+10.6%$995.90M$117.61M0.00450NUVBNuvation Bio2.2597 of 5 stars$2.88-0.7%$7.33+154.6%-8.5%$992.59M$7.87M0.0060News CoveragePositive NewsVERVVerve Therapeutics2.128 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110VALNValneva1.9794 of 5 stars$9.43-19.0%$16.00+69.7%+17.9%$990.49M$183.52M0.00700Short Interest ↑Gap UpHigh Trading VolumeMLYSMineralys Therapeutics1.6996 of 5 stars$14.74-1.0%$32.25+118.8%+132.6%$986.80MN/A0.0028Trending NewsAnalyst ForecastGap DownATAIatai Life Sciences3.5046 of 5 stars$4.74+3.7%$11.25+137.3%+253.1%$979.53M$310K-6.8780High Trading VolumeIOVAIovance Biotherapeutics4.2944 of 5 stars$2.53-5.9%$11.90+370.4%-81.2%$973.39M$164.07M0.00500Positive NewsUPBUpstream Bio2.2576 of 5 stars$16.73-5.1%$56.50+237.7%N/A$950.42M$2.37M0.0038News CoveragePositive NewsGap Up Related Companies and Tools Related Companies PRAX Competitors CRMD Competitors CRON Competitors NUVB Competitors VERV Competitors VALN Competitors MLYS Competitors ATAI Competitors IOVA Competitors UPB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:VOR) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
